

Title (en)

ANTI-ERBB3 ANTIBODIES AND USES THEREOF

Title (de)

ANTI-ERBB3-ANTIKÖRPER UND VERWENDUNGEN DAVON

Title (fr)

ANTICORPS ANTI-ERBB3 ET LEURS UTILISATIONS

Publication

EP 2760893 B1 20180912 (EN)

Application

EP 12768988 A 20120921

Priority

- US 201161541312 P 20110930
- US 201161557460 P 20111109
- US 201261614565 P 20120323
- US 2012056446 W 20120921

Abstract (en)

[origin: US2013084297A1] The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

IPC 8 full level

C07K 16/28 (2006.01)

CPC (source: EP US)

A61K 31/517 (2013.01 - EP US); **A61K 31/5377** (2013.01 - EP US); **A61K 39/3955** (2013.01 - US); **A61K 39/39558** (2013.01 - US); **A61P 1/04** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/2863** (2013.01 - EP US); **C07K 16/3023** (2013.01 - US); **C07K 16/3046** (2013.01 - US); **C07K 16/3053** (2013.01 - US); **C07K 16/32** (2013.01 - EP US); **C07K 16/40** (2013.01 - US); **A61K 2039/505** (2013.01 - EP US); **A61K 2039/507** (2013.01 - EP US); **C07K 2317/21** (2013.01 - EP US); **C07K 2317/34** (2013.01 - EP US); **C07K 2317/56** (2013.01 - US); **C07K 2317/565** (2013.01 - US); **C07K 2317/73** (2013.01 - EP US); **C07K 2317/76** (2013.01 - EP US); **C07K 2317/77** (2013.01 - EP US); **C07K 2317/92** (2013.01 - EP US); **C12N 5/10** (2013.01 - US); **C12N 15/63** (2013.01 - US); **C12N 2510/00** (2013.01 - US); **C12N 2800/00** (2013.01 - US)

Citation (examination)

- WO 2010108127 A1 20100923 - GENENTECH INC [US], et al
- WO 2007077028 A2 20070712 - U3 PHARMA AG [DE], et al
- WO 2008100624 A2 20080821 - MERRIMACK PHARMACEUTICALS INC [US], et al
- WO 2011044311 A2 20110414 - MERCK SHARP & DOHME [US], et al
- WO 2010108127 A1 20100923 - GENENTECH INC [US], et al
- WO 2007077028 A2 20070712 - U3 PHARMA AG [DE], et al
- WO 2008100624 A2 20080821 - MERRIMACK PHARMACEUTICALS INC [US], et al
- WO 2011044311 A2 20110414 - MERCK SHARP & DOHME [US], et al

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

US 2013084297 A1 20130404; **US 8791244 B2 20140729**; AR 088171 A1 20140514; AU 2012316402 A1 20140417; AU 2012316402 B2 20170420; AU 2017206185 A1 20170803; AU 2017206185 B2 20190117; BR 112014007382 A2 20170404; CA 2849508 A1 20130404; CA 2849508 C 20201222; CL 2014000758 A1 20140822; CN 103917562 A 20140709; CN 103917562 B 20160706; CO 6940383 A2 20140509; EA 028879 B1 20180131; EA 201490717 A1 20140930; EA 201791393 A2 20171130; EA 201791393 A3 20180330; EP 2760893 A2 20140806; EP 2760893 B1 20180912; ES 2694153 T3 20181218; HK 1200468 A1 20150807; IL 231318 A0 20140430; IL 231318 B 20180329; IL 251697 A0 20170629; IN 3042CHN2014 A 20150703; JP 2014530215 A 20141117; JP 2018080185 A 20180524; JP 6271432 B2 20180131; JP 6563472 B2 20190821; KR 20140069331 A 20140609; MX 2014003711 A 20140722; MX 357391 B 20180706; NZ 623438 A 20151030; SG 11201400150T A 20140328; TW 201329103 A 20130716; TW 201809012 A 20180316; US 10632194 B2 20200428; US 11771762 B2 20231003; US 2014308279 A1 20141016; US 2016144029 A1 20160526; US 2018036406 A1 20180208; US 2020276307 A1 20200903; US 9284380 B2 20160315; US 9827310 B2 20171128; WO 2013048883 A2 20130404; WO 2013048883 A3 20130627; ZA 201401424 B 20160127

DOCDB simple family (application)

US 201213623885 A 20120921; AR P120103601 A 20120927; AU 2012316402 A 20120921; AU 2017206185 A 20170718; BR 112014007382 A 20120921; CA 2849508 A 20120921; CL 2014000758 A 20140327; CN 201280045274 A 20120921; CO 14092568 A 20140430; EA 201490717 A 20120921; EA 201791393 A 20120921; EP 12768988 A 20120921; ES 12768988 T 20120921; HK 15100956 A 20150128; IL 23131814 A 20140305; IL 25169717 A 20170412; IN 3042CHN2014 A 20140423; JP 2014533618 A 20120921; JP 2017248591 A 20171226; KR 20147011692 A 20120921; MX 2014003711 A 20120921; NZ 62343812 A 20120921; SG 11201400150T A 20120921; TW 101135734 A 20120928; TW 106116405 A 20120928; US 2012056446 W 20120921; US 201414308527 A 20140618; US 201615011978 A 20160201; US 201715793756 A 20171025; US 202016848752 A 20200414; ZA 201401424 A 20140225